Recent News

Association Between Pretransplant Molecular MRD and Outcomes in AML

Novel Combination Results in Anticancer ‘Double Whammy’ in AML

TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML

TCT 2021: CPX-351 Versus Chemotherapy for High-Risk of Secondary AML

TCT 2021: Effects of HSCT After Azacitidine Therapy for AML

Does Exposure to Occupational Pesticides Increase the Risk for AML?

TCT 2021: JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML

Eprenetapopt Plus Azacitidine Under Study in TP53-Mutant AML

Decitabine Plus Venetoclax Versus Chemotherapy Among Older Patients With AML

Why Do Some Patients With Newly Diagnosed AML Decline Treatment?

Newly Diagnosed FLT3-Mutant AML: Sorafenib Plus Chemotherapy

Gilteritinib Plus Chemotherapy for Newly Diagnosed AML

Intravenous and Subcutaneous Cytarabine for Standard Induction Therapy in AML

Quizartinib-Based Triplet Therapy for FLT3-ITD–Mutated AML

5-Year Results for CPX-351 in Older Adults With High-Risk AML

Safety Profile of Midostaurin in Older Patients With AML

Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia

Race Matters Significantly in AML Outcomes, Study Data Show

ASH 2020: Phase III Trial of Gilteritinib Plus Azacitidine for FLT3-Mutated AML

ASH 2020: Gilteritinib Versus Salvage Chemotherapy for FLT3-Mutated AML

COVID-19 and Acute Leukemias: German Investigators Share Treatment Experiences

ASH 2020: Venetoclax Plus CPX-351 in AML

ASH 2020: Early Results in Targeting CD47 in AML

FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML

Altered Bone Marrow Niche: Predicting Outcomes in AML?

Precision Medicine in AML Early Results From Beat AML Master Trial

Relapsed AML in Children and Hematopoietic Cell Transplantation

Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML

Suicide Risk Factors for Patients With AML and Other Leukemias

Anti–TIM-3 Monoclonal Antibody Under Study in AML

Rare Occurrence of Secondary CML After AML: Case Study

Novel Treatment Under Study in Transplantation-Eligible Patients With AML

Early Results With Eftozanermin Alfa Plus Venetoclax in AML

How Does Minimal Residual Disease Impact Clinical Outcomes in Acute Leukemias?

Venetoclax Combination Therapy for Acute Myeloid Leukemia Approved by FDA

Potential of IDH1 Inhibitors in AML Prior to Hematopoietic Cell Transplantation

SIERRA Trial Update on Novel Conditioning Regimen for Older Patients With AML

Pediatric AML: Combination Therapy With Venetoclax and Azacitidine

SOHO 2020: GI Side Effects for Patients With AML Treated With CC-486

SOHO 2020: Survival Update From BRIGHT Trial of Glasdegib-Based Therapy for AML

Long-Term Psychosocial and Neurocognitive Impact of Childhood AML

SOHO 2020: Elevated LDH Levels and Overall Survival in AML

Clinical Implications of Condensing HDAC Regimen in Treatment of AML

NPM1‐Mutant AML and COVID-19: Modified Protocols for Monitoring Treatment Response

Stem Cell Transplantation and AML: WT1 Expression and Outcomes